Targeting multiple dyslipidemias with fixed combinations - Focus on extended release niacin and simvastatin

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1001-1009

  Pandian, Anbu ^a   Arora, Anjali ^b   Sperling, Laurence S ^a   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SIR GANGA RAM HOSPITAL   (India)

Author keywords

Dyslipidemia; HDL cholesterol; Niacin; Statin; Triglyceride

Indexed keywords

ACETYLSALICYLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN INHIBITOR; SIMCOR; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTERY DISEASE; ATHEROSCLEROSIS; BACKACHE; BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; NONHUMAN; PATIENT COUNSELING; PATIENT EDUCATION; PRURITUS; RETINA MACULA EDEMA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; PATIENT COMPLIANCE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 56849098109     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Adler AI, Neil HA, Manley SE, et al. 1999. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J, 138:S353-S9.
2. Aim High: Niacin plus statin to prevent vascular events. Clinical trials. gov-NCT 00120289.
3. Aktories K, Schultz G, Jakobs KH. 1983. Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes. FEBS Lett, 156:88-92.
4. Alvarsson M, Grill V. 1996. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest, 56:563-70.
5. Ballantyne CM, Davidson M, McKenney J, et al. 2007. Safety and efficacy of a combination of extended-release niacin and simvastatin in patients with dyslipedemia (SEACOAST) - a dose ranging study [abstract]. AHA Scientific Conference, Chicago.
6. Bays H. 2008. Safety of niacin and simvastatin combination therapy. Am J Cardiol, 101:3-8.
7. Butcher RW, Baird CE, Sutherland EW. 1968. Effects of lipolytic and antilipolytic substances on adenosine 3′, 5′-monophosphate levels in isolated fat cells. J Biol Chem, 243:1705-12.
8. Brown BG, Zhao XQ, Chait A, et al. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med, 345:1583-92.
9. Canner PL, Berge KG, Wenger NK, et al. 1986. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol, 8:1245-55.
10. Chang AM, Smith MJ, Galecki AT, et al. 2006. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab, 91:3303-9.
11. Cheng K, Wu TJ, Wu KK, et al. 2006. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A, 103:6682-7.
12. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA, 1975.231:360-381.
13. Elam MB, Hunninghake DB, Davis KB, et al. 2000. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT [Arterial Disease Multiple Intervention Trial] study. A randomized trial. JAMA, 284:1263-70.
14. Ganji SH, Kamanna VS, Kashyap ML. 2003. Niacin and cholesterol: role in cardiovascular disease. J Nutr Biochem, 14:299-305.
15. Garg A, Grundy SM. 1990. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA, 264:723-6.
16. Gibbons LW, Gonzalez V, Gordon N, et al. 1995. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med, 99:378-85.
17. Ginsberg HN. 2000. Insulin resistance and cardiovascular disease. J Clin Invest, 106:453-8.
18. Goldberg A, Alagona P Jr, Capuzzi DM, et al. 2000. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol, 85:1100-5.
19. Grundy et al. 2004. Implications of the recent clinical trials for the National Education Program Adult Treatment Panel Guidelines - Circulation: Introduction.
20. Grundy SM, Vega GL, McGovern ME, et al. for the Diabetes Multicenter Research Group. 2002. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med, 162:1568-76.
21. Guyton JR, Blazing MA, Hagar J, et al. 2000. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med, 160:1177-84.
22. Guyton JR, Blazing MA, Hagar J, et al. 2000. Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterol. Arch Intern Med, 160:1177-84.
23. Guyton JR, Goldberg AC, Kreisberg RA, et al. 1998. Effectiveness of once-nightly dosing of extended release macin alone and in combination for hypercholesterolemia. Am J Cardiol, 82:737-43.
24. Hodis HN, Mack WJ, LaBree L, et al. 1998. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med, 128:262-9.
25. Health Protection Study-2-(HPS2-THRIVE). clinicaltrials.gov-00461360.
26. Jin FY, Kamanna VS, Kashyap ML. 1999. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol, 19:1051-9.
27. Jin FY, Kamanna VS, Kashyap ML. 1997. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 17:2020-8.
28. Kahn SE, Beard JC, Schwartz MW, et al. 1989. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes, 38:562-8.
29. Kastelein JJP. 2005. The realities of dyslipidaemia: what do the studies tell us? Eur Heart J, 7(Suppl F):F27-F33.
30. Karas RH, AlSheikh-Ali AA. 2008: The safety of niacin in the US Food and Drug Administration Adverse Event Reporting Database. Am J Cardiol, 101:10-3.
31. Kelly JJ, Lawson JA, Campbell LV, et al. 2000. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens, 14:567-72.
32. Knopp RH, Ginsberg J, Albers JJ, et al. 1985. Contrasting effects of unmodified andtime-release forms of macin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism, 34:642-50.
33. Knopp RH, Alagona P, Davidson M, et al. 1998. Equivalent efficacy of a time-release form of niacin (Niaspan) given once a-night versus plain niacin in the management of hyperlipidemia. Metabolism, 47:1097-104.
34. Kos Pharmaceuticals (currently) Abbott Pharmaceuticals DN1628V4-simcor-021408 Prescribing Information 2008.
35. Krauss RM. 2004. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496-504.
36. Lorenzen A, Stannek C, Lang H, et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001. 59:349-57.
37. McGovern ME. 2005. Niaspan®: creating a new concept for raising HDL-cholesterol. Eur Heart J, 7(Suppl F):F41-F7.
38. McKenney JM, Proctor ID, Harris S, et al. 1994. A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients. JAMA, 271:672-7.
39. Meyers CD, Carr MC, Park S, et al. 2003. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med, 139:996-1002.
40. Morgan JM, Capuzzi DM, Guyton JR, et al. 1996. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther, 1:195-202.
41. Morrow JD, Awad JA, Oates JA, et al. 1992. Identification of skinas a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol, 98:812-15.
42. National Cholesterol Education Program (NCEP). 2002. Expert panel on detection (third report), evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation, 106:3143-421.
43. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006. 60:707-15.
44. Paolini JF, Mitchell YB, Reyes R, et al. 2008. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipedemia. Am J Cardiol, 101:625-8.
45. Poynten AM, Gan SK, Kriketos AD, et al. 2003. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism, 52:699-704.
46. Rasouli N, Hale T, Kahn SE, et al. 2005. Effects of short-term experimental insulin resistance and family history of diabeteson pancreatic beta-cell function in nondiabetic individuals. J Clin Endocrinol Metab, 90:5825-33.
47. Robinson JG, Smith B, Maheshwari N, et al. 2005. Pleiotrophic effects of statins - benefits beyond LDL reduction? J Am Coll Cardiol, 46:1855-62.
48. Rubic T, Trottmann M, Lorenz RL. 2004. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol, 67:411-9.
49. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simmastatin Survival Study (4S). Lancet, 344:1383-9.
50. Soga T, Kamohara M, Takasaki J, et al. 2003. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun, 303:364-9.
51. Soudijn W, van Wijngaarden I, Ijzerman AP. 2007. Nicotinic acid receptor subtypes and their ligands. Med Res Rev, 27:417-33.
52. Stern RH, Spence JD, Freeman DJ, et al. 1991. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther, 50:66-70.
53. Taylor AJ, Sullenberger LE, Lee HJ, et al. 2004. Arterial Biology for the Treatment Effects of Reducing Cholesterol 2 (ARBITER 2 Study). Circulation, 110:3512-7.
54. Thoenes M, Oguchi A, Nagamia S, et al. 2007. The effects of extended-release niacin on carotid intimal medial thickness, endothelial ftinction, and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract, 61:1942-8.
55. Tunaru S, Kero J, Schaub A, et al. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med, 9:352-5.
56. Wang W, Basinger A, Neese RA, et al. 2001. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab, 280:E540-E7.
57. Wise A, Foord SM, Fraser NJ, et al. 2003. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem, 278:9869-74.